My take on the standing ovation for DESTINY Breast 04
Traztuzumab Deruxtecan vs. Investigator choice after endocrine therapy and 1 or 2 chemotherapies for HER2 low

4.66 PD1 Ab for MSI H Stage II/ III Rectal Cancer; A 100% CR rate??

Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service.

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com